Key TakeawaysCOVID-19 mRNA vaccines may enhance immune checkpoint inhibitor efficacy in NSCLC and melanoma, improving overall survival.mRNA vaccines activate type I interferon responses, enhancing antigen presentation and CD8+ T-cell activation, sensitizing tumors to ICIs.The survival benefit was specific to ICIs, with no similar improvement in patients receiving chemotherapy or other vaccines.Off-the-shelf mRNA vaccines could serve […]
